Although much effort has been done to lower LDL-cholesterol concentrations, there is still a substantial risk for cardiovascular disease (CVD). Another strategy to lower the risk for CVD is elevating the HDL-cholesterol (HDL-C). Both in vitro and in vivo studies showed that elevating HDL-C or apolipoprotein A-I (Apo A-I) levels protect against CVD. However, despite many initiatives, no new widely applicable intervention strategies with proven efficacy have been developed. Epidemiologic studies have shown that a higher polyphenol intake is associated with a lower risk for CVD. Resveratrol, a polyphenol, could, through several beneficial mechanisms, exert a positive effect on formation of atherosclerotic plaques and thus on developing CVD. It has been shown in animals that resveratrol elevates PPAR-alpha activity. This may lead to elevated apo A-I and HDL-C levels in the blood. However, these effects are not shown in human intervention studies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
50
2 x 75 mg resveratrol each day, for 4 weeks
Maastricht University Medical Center
Maastricht, Netherlands
ApoA-I level
Time frame: Measured at baseline, after 4 weeks, 8 weeks and 12 weeks
Endothelial function and arterial stiffness
Time frame: Measured in weeks 4 and 12
Endothelial function of the retinal microvasculature
Time frame: Measured in weeks 4 and 12
Lipid and glucose metabolism during the fasting and postprandial phase
Time frame: Measured at baseline, after 4 weeks, 8 weeks and 12 weeks
biomarkers for low-grade systemic inflammation and endothelial function
Time frame: Measured at baseline, after 4 weeks, 8 weeks and 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.